

CITATION REPORT

List of articles citing

Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study

DOI: 10.1097/00124743-199904000-00003

Journal of Clinical Rheumatology, 1999, 5, 49-55.

Source: <https://exaly.com/paper-pdf/31055555/citation-report.pdf>

Version: 2024-04-05

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	Management of crystal arthritis. 1999 , 38, 912-6		13
110	How well have diagnostic tests and therapies for gout been evaluated?. 1999 , 11, 441-5		23
109	Gout update: from lab to the clinic and back. 2000 , 12, 213-8		13
108	How well have diagnostic tests and therapies for gout been evaluated?. 2000 , 11, 71-76		3
107	Gout and other crystal-associated arthropathies. 2000 , 14, 445-60		30
106	Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. 2000 , 35, E10		33
105	Crystal-associated arthritis in the elderly. 2000 , 26, 527-46, vii		16
104	Artropatías microcristalinas I. Hiperuricemia y gota. 2001 , 8, 1765-1772		
103	Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. 2001 , 3, 29-35		37
102	Efficacy and safety of desensitization to allopurinol following cutaneous reactions. 2001 , 44, 231-8		93
101	Update on gout. 2002 , 47, 563-5		5
100	Hyperuricemia and gout. 2003 , 5, 227-34		42
99	Current management of gout in patients unresponsive or allergic to allopurinol. 2004 , 71, 481-5		42
98	Comment traiter un goutteux résistant ou allergique à l'Allopurinol en 2004 ?. 2004 , 71, 860-864		1
97	Artritis por microcristales (1). Gota. 2005 , 9, 2081-2088		
96	[Not Available]. 2005 , 1, 139-41		
95	Crystal-associated arthritis in the elderly. 2005 , 21, 491-511, v-vi		6

94	Treatment of crystal arthropathy--history and advances. 2006 , 32, 333-57, vi	11
93	EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). 2006 , 65, 1312-24	805
92	Gout: can we create an evidence-based systematic approach to diagnosis and management?. 2006 , 20, 673-84	19
91	Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. 2006 , 55, 786-90	49
90	Therapeutic advances in gout. 2007 , 19, 122-7	30
89	Imaging modalities and monitoring measures of gout. 2007 , 19, 128-33	39
88	Crystal-associated arthritis in the elderly. 2007 , 33, 33-55	21
87	Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. 2007 , 57, 1324-8	117
86	Les nouveaux traitements de la goutte. 2007 , 74, 624-626	
85	New treatments for gout. 2007 , 74, 313-5	6
84	Pain management in gout. 2008 , 12, 418-22	3
83	Treatment-failure gout: a moving target. 2008 , 58, 2587-90	45
82	A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?. 2008 , 31, 643-65	191
81	[Treatment of Gout: Reflections From the GEMA Study]. 2008 , 4 Suppl 2, 41-4	6
80	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. 2008 , 3, 421-427	5
79	Management of gout. 2008 , 37, 81-9	9
78	Gout: an evidence-based review. <i>Journal of Clinical Rheumatology</i> , 2008 , 14, S55-62	1.1 48
77	Treating to target: a strategy to cure gout. 2009 , 48 Suppl 2, ii9-ii14	98

76	Gout and Hyperuricemia: New Guidelines and Treatments. 2009 , 22, 104-115		
75	Gout--what are the treatment options?. 2009 , 10, 1319-28		29
74	Artritis microcristalinas. 2009 , 10, 2205-2210		
73	Gout: new advances in the diagnosis and management of an old disease. 2009 , 4, 203-220		6
72	Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. 2011 , 40, 444-7		3
71	Gout: past, present, and future. 2011 , 7, 217-219		
70	[Gout: past, present, and future]. 2011 , 7, 217-9		1
69	The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. <i>Journal of Clinical Rheumatology</i> , 2011 , 17, 1-6	1.1	111
68	Treating gout in patients with comorbidities. 2011 , 6, 625-633		1
67	Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. 2011 , 40, 483-500		39
66	Quality of care in patients with gout: why is management suboptimal and what can be done about it?. 2011 , 13, 154-9		36
65	Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. 2012 , 42, 166-78		32
64	Evaluation and treatment of gout as a chronic disease. 2012 , 29, 935-46		16
63	Xanthine Oxidase Inhibitor Treatment of Hyperuricemia. 2012 , 154-173		1
62	Uricosuric Therapy of Hyperuricemia in Gout. 2012 , 148-153		2
61	Eficacia y efectividad de los tratamientos reductores de la uricemia. 2013 , 14, 8-13		
60	Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. 2013 , 76, 932-8		26
59	Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. 2013 , 65, 1636-42		50

58	Management of Hyperuricemia and Gout. 2013 , 291-385	
57	Urate-lowering therapy: uricosurics. 2013 , 174-188	1
56	Treatment of gout in patients after organ transplantation. 2013 , 3, 215-220	1
55	Treatment of Hyperuricemia in Gout. 2014 , 41-52	
54	Rapid crystal dissolution in gout: is it feasible and advisable?. 2014 , 9, 395-401	2
53	Uricosuric medications for chronic gout. 2014 , CD010457	19
52	Clinical manifestations and diagnosis of gout. 2014 , 40, 193-206	41
51	Allopurinol for chronic gout. 2014 , CD006077	29
50	Urate-lowering therapy: current options and future prospects for elderly patients with gout. 2014 , 31, 777-86	13
49	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. 2014 , 73, 328-35	182
48	[Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations]. 2014 , 73, 836-42	6
47	Disease Overview. 2014 , 1-12	
46	Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. 2015 , 9, 5033-49	4
45	Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. 2015 , 16, 58	107
44	Advances in pharmacotherapy for the treatment of gout. 2015 , 16, 533-46	21
43	An open-label, 6-month study of allopurinol safety in gout: The LASSO study. 2015 , 45, 174-83	63
42	Diagnose und Therapiestandard der Gicht in Österreich. 2015 , 14, 18-24	1
41	Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. 2015 , 18, 341-51	35

40	Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. 2015 , 54, 981-93	15
39	Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. 2016 , 6, 33082	35
38	Gout: optimizing treatment to achieve a disease cure. 2016 , 7, 135-44	22
37	Treat-to-target (T2T) recommendations for gout. 2017 , 76, 632-638	70
36	Critical revision of the medical treatment of gout in Brazil. 2017 , 57, 346-355	3
35	Gout: An old disease in new perspective - A review. 2017 , 8, 495-511	200
34	The British Society for Rheumatology Guideline for the Management of Gout. 2017 , 56, e1-e20	104
33	Revisão crítica do tratamento medicamentoso da gota no Brasil. 2017 , 57, 346-355	6
32	Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. 2017 , 56, 1144-1153	50
31	Severe gout: Strategies and innovations for effective management. 2017 , 84, 541-546	16
30	2016 updated EULAR evidence-based recommendations for the management of gout. 2017 , 76, 29-42	726
29	Goutte sévère: stratégies et innovations pour une prise en charge efficace. 2017 , 84, 480-485	
28	Urate-Lowering Therapy. 2017 , 1061-1074.e3	2
27	Managing Gout in the Patient with Renal Impairment. 2018 , 35, 263-273	6
26	Treat to target in gout. 2018 , 57, i20-i26	13
25	Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. 2018 , 20, 47	3
24	Benzbromarone: A Review. 2018 ,	
23	Benzbromarone in the treatment of gout. 2019 , 59, 37	24

22	Treatment Guidelines. 2019 , 141-153	1
21	Treat to Target. 2019 , 179-183	
20	Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. 2020 , 2, e281-e291	5
19	Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. 2020 , 39, 1633-1648	2
18	Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. 2021 , 5, rkaa073	2
17	Contentious Issues in Gout Management: The Story so Far. 2021 , 13, 111-122	2
16	Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials. 2021 , 12, 690557	3
15	CRISPR-Cas9-mediated reactivation of the uricase pseudogene in human cells prevents acute hyperuricemia. 2021 , 25, 578-584	1
14	Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. 2017 , 8, 555-560	38
13	Current and future therapeutic options for the management of gout. 2010 , 17, 402-17	9
12	An old disease with new insights: Update on diagnosis and treatment of gout. 2014 , 1, 72-77	9
11	Jicht en Pseudo-Jicht. 2000 , 206-211	
10	The kidney and rheumatic disease. 2011 , 329-345.e3	
9	Clinical Aspects of Gout and Associated Disease States. 2013 , 91-185	
8	Antihyperuricemic Agents. 2013 , 1001-1013	
7	Gout. What's up doc?. <i>Medicina Clínica</i> , 2022 ,	1
6	A Case of Recent Liver Injury Induced by Benzbromarone. <i>Reports</i> , 2022 , 5, 8	0.4
5	Gout. What's up doc?. <i>Medicina Clínica (English Edition)</i> , 2022 , 158, 615-621	0.3

4 Therapeutics in rheumatology and the kidney.

3 Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. **2023**, 60, 152191

o

2 Towards a more ambitious uricemia target to improve joint and cardiovascular outcomes in gout. 20-25

o

1 The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients. **2023**,

o